Taken together, the findings suggest that SAMHD1 may be a potential prognostic biomarker in the adjuvant and neoadjuvant setting, and that the combination of cytotoxic chemotherapy and USP7 inhibition might improve chemotherapy sensitivity in various cancers (Fig. 8H). Here, SAMHD1 is linked to cancer.